• Werewolf Therapeutics disclosed an oversubscribed private placement raising USD 150 million alongside its planned all-stock merger with Ambros.
• Financing expected to close with the merger through issuance of common stock, pre-funded warrants.
• Proceeds slated to fund operations into 1H 2029, covering Phase 3 CRPS-RISE topline results expected in 2028.
• Funding also supports a planned NDA submission for neridronate in CRPS-1, a condition with no FDA-approved therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.